azd-2624

Small moleculeexperimental

Clinical trial activity

6 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2008 (NCT00696865)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1
Mol. weight
459.57 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-((methylsulfonyl)amino)-2-phenyl-n-(1-phenylpropyl)quinolin-4-carboxamide
  • azd2624
  • azd2624
  • azd2624
  • azd2624
  • azd 2624
  • azd-2624
  • azd-2624
  • azd-2624
  • azd-2624
  • azd4901
  • azd4901
  • mle4901
  • mle4901

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02865915Phase 2Jul 1, 2016Covance, Medpace, Inc., Millendo Therapeutics, Inc.
NCT02668185Phase 2Feb 1, 2016AstraZeneca, Medical Research Council, National Institute for Health Research, United Kingdom, University of London
NCT01872078Phase 2Jun 1, 2013AstraZeneca, University of Oxford
NCT00867685Phase 1Mar 1, 2009AstraZeneca
NCT00686998Phase 2May 1, 2008AstraZeneca
NCT00696865Phase 1May 1, 2008AstraZeneca, Kitasato University
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit5422008
CovanceFor profit1012016
Kitasato UniversityAcademic/Hospital1012008
Medical Research CouncilGovernment1012016
Medpace, Inc.For profit1012016
Millendo Therapeutics, Inc.For profit1112016
National Institute for Health Research, United KingdomGovernment1012016
University of LondonAcademic/Hospital1112016
University of OxfordAcademic/Hospital1012013
9 organizations
Page 1 / 1